

Review

The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma

Qiong Wu ¹ , Anders E. Berglund ² , Robert J. Macaulay ³  and Arnold B. Etame ^{1,*} 

¹ Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA

² Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA

³ Departments of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA

* Correspondence: arnold.etame@moffitt.org

Abstract: Glioblastoma (GBM) is the most common yet uniformly fatal adult brain cancer. Intra-tumoral molecular and cellular heterogeneities are major contributory factors to therapeutic refractoriness and futility in GBM. Molecular heterogeneity is represented through molecular subtype clusters whereby the proneural (PN) subtype is associated with significantly increased long-term survival compared to the highly resistant mesenchymal (MES) subtype. Furthermore, it is universally recognized that a small subset of GBM cells known as GBM stem cells (GSCs) serve as reservoirs for tumor recurrence and progression. The clonal evolution of GSC molecular subtypes in response to therapy drives intra-tumoral heterogeneity and remains a critical determinant of GBM outcomes. In particular, the intra-tumoral MES reprogramming of GSCs using current GBM therapies has emerged as a leading hypothesis for therapeutic refractoriness. Preventing the intra-tumoral divergent evolution of GBM toward the MES subtype via new treatments would dramatically improve long-term survival for GBM patients and have a significant impact on GBM outcomes. In this review, we examine the challenges of the role of MES reprogramming in the malignant clonal evolution of glioblastoma and provide future perspectives for addressing the unmet therapeutic need to overcome resistance in GBM.

Keywords: glioblastoma; intra-tumoral heterogeneity; mesenchymal reprogramming; clonal evolution; anti-GBM therapy; tumor microenvironment; therapeutic resistance



Citation: Wu, Q.; Berglund, A.E.; Macaulay, R.J.; Etame, A.B. The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma. *Cells* **2024**, *13*, 942. <https://doi.org/10.3390/cells13110942>

Academic Editor: Swapan K. Ray

Received: 30 April 2024

Revised: 26 May 2024

Accepted: 29 May 2024

Published: 30 May 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Glioblastoma (GBM) is the most common infiltrative primary central nervous system (CNS) malignancy with a median survival of 15 months [1–3]. While genetic and environmental factors have been postulated as contributory factors, the overwhelming majority of GBM cases are sporadic. Advances in GBM epidemiology have resulted in the appreciation of biological subtypes and also the relevance of these subtypes to GBM outcomes [4]. Nevertheless, there is a substantial unmet need for impactful therapeutic strategies that can significantly improve GBM outcomes beyond the standard of care.

GBM standard therapy entails multimodal strategies of maximum surgical resection, temozolomide (TMZ) chemotherapy, and radiotherapy. However, tumor recurrence is universal and frequent. Tumor heterogeneity, the tumor infiltrative growth pattern, and the central nervous system location present significant challenges to current therapeutic approaches, leading to disease recurrence. As a consequence, therapeutic resistance remains a largely unaddressed phenomenon in GBM. Molecular surrogates of favorable GBM biology and therapeutic response have been proposed [5–10]. One of the most impactful genetic alterations that govern glioma tumor biology and permit clinically relevant classification is *IDH* genomic status [5,10]. The importance of the NADP(+)-dependent

isocitrate dehydrogenases protein encoded by *IDH1* and *IDH2* genes has been known for over a decade, whereby *IDH1* mutations are present in high-grade gliomas that develop from low-grade gliomas, whereas *IDH*-wildtype GBMs arise de novo and usually have a poorer prognosis [5,10]. Another molecular prognosticating marker of chemotherapeutic response is the promoter methylation status of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) [7–9]. MGMT is epigenetically regulated in high-grade gliomas [8]. Epigenetic silencing of MGMT sensitizes GBMs to TMZ and improves survival, thereby rendering MGMT methylation status as one of the most important biomarkers to predict TMZ response [7]. Thus far, MGMT methylation status and mutation in *IDH1* are the most impactful independent prognosticating factors in the clinical management of GBM [6].

Beyond the standard of care treatment, targeted inhibition of crucial growth factor pathways [11], immune-checkpoint inhibitors, and tumor vaccine strategies [12–16] have been extensively explored in GBM for therapeutic efficacy. To date, none of the above strategies have been effective [13,17–21]. A combination of immunosuppressive microenvironment factors, as well as tumor molecular and cellular heterogeneity factors, have been postulated as contributors to therapeutic futility in GBM [22–27]. Furthermore, treatment-induced mesenchymal (MES) reprogramming has emerged as the leading cause of intra-tumoral heterogeneity, malignant clonal evolution, and subsequent lethality in GBM [28–30]. Hence, systematic characterization of malignant reprogramming mechanisms can provide valuable insights into novel therapeutic interventions in GBM. This review will highlight the role of MES reprogramming in therapeutic futility in glioblastoma and provide future perspectives for addressing this formidable challenge in GBM.

2. GBM Stem Cells in the GBM Microenvironment

Regional heterogeneity is both a histopathological and a radiographic hallmark of GBM, whereby there are regions of central hypoxia and necrosis surrounded by a pseudo-palisading, a proliferative angiogenic zone that is enhanced in contrast magnetic resonance imaging (MRI) [31]. Through bulk tumor analysis, it has been demonstrated that the GBM heterogeneous subclones evolve from a subset of stem-like cells known as the GBM stem cells (GSCs), which harbor distinct genetic alterations [32] and originate from neural stem cells of the subventricular neurogenesis zone [33,34]. GSCs have self-renewal capabilities and are characterized by evaluating the expression of specific gene markers reflective of stemness including CD133, Sox2, and Nestin [35,36] (Figure 1). In light of their high proliferation rate and molecular heterogeneity, GSCs are highly resistant to GBM therapy and serve as a critical nidus for disease recurrence [37,38]. Interestingly, the GSCs within the perinecrotic hypoxic niche and angiogenic niche are highly proliferative, relative to GSCs of the brain-invasive front [39]. Post-treatment recurrence is believed to be secondary to the repopulation of new tumors by GSCs that persist despite treatment [40]. Therefore, there is overwhelming evidence that GSCs are the primary contributor to tumorigenicity, treatment-induced resistance, and recurrence. Furthermore, there is evidence that GSCs mediate therapeutic resistance through multiple mechanisms, impacting DNA repair and drug efflux systems [41,42] (Figure 1).

Given the apical location of GSCs within the GBM cellular hierarchy, GSCs play a critical role in GBM tumorigenicity and cell fate determination [39,43,44]. GSCs co-exist with differentiated tumor cells, astrocytes, and immune cells within the perivascular niche of GBM [39]. Complex interactions within this perivascular microenvironment sustain GSC survival and proliferation. Immune cells within the tumor microenvironment include tumor-associated macrophages (TAMs), microglia, myeloid-derived suppressor cells (MDSCs), neutrophils, and monocytes [39,45]. TAMs and microglia play vital roles in GSC tumorigenesis through the upregulation of matrix metalloproteinase 9 (MMP9) expression via transforming growth factor- β (TGF- β) signaling [46,47]. Furthermore, the maintenance of GSC self-renewal is sustained through tumor cell-induced paracrine proliferation and migration of astrocytes [48,49].




Figure 1. Malignant reprogramming of GSCs in GBM. Schematic representation of the impacts of GSCs on GBM tumor propagation. GSCs contribute to therapeutic resistance, the hypoxic microenvironment, MES reprogramming, tumor cell self-renewal, angiogenesis, and tumor invasion.

3. Heterogeneity in GBM

Intra-tumoral heterogeneity, both at the cellular and molecular genetics level (Table 1), is a pathognomonic hallmark of GBM that is responsible for therapeutic resistance and poor outcomes in GBM [27]. Hence, a deeper understanding of the nature of cellular and molecular heterogeneity in GBM is essential to developing therapies that are impactful in GBM. Over the last two decades, there have been significant advances in deciphering critical genetic alterations in GBM, which have facilitated both tumor characterization and an enhanced appreciation of the GBM landscape. The Cancer Genome Atlas (TCGA) was the seminal study that characterized critical molecular pathway aberrations that were highly featured in GBM through the comprehensive characterization of over 600 GBM patient tissues [50]. In particular, mutations in *TP53*, receptor tyrosine kinase genes (RTKs), and *RB* were identified as the most common critical genetic alterations in GBM [51]. Loss of function of the tumor suppressor gene *TP53* through mutation or alterations of other p53 signaling components such as MDM2 promotes the malignant reprogramming of tumor cells [52–54]. *RB* signaling, which is tumor suppressive, is highly dysregulated in GBM through aberrations of crucial activators of p53 such as CDK4 amplification and CDKN2A deletion in GBM [55]. In addition, pervasive alterations to RTK signaling pathways, including EGFR, PDGF, and TGF- β , facilitate GBM oncogenesis through the downstream activation of oncogenic pathways [39]. Signal transduction through RTKs facilitates important oncogenic processes at the cellular level including proliferation, apoptosis resistance, and invasion [56,57]. Amplification of EGFR as well as constitutive-active mutants (EGFRvIII) represents the most common alteration in GBM [58,59]. Similarly, PDGFRA amplification [60] and deletional mutations [61] are commonly encountered in GBM. Downstream activations of RAS/MAPK and PI3K/AKT/mTOR signaling pathways through mutations and deletions of pathway components appear to be common oncogenic and malignant propagating events in GBM [60]. The diverse activations and complex interactions of multiple oncogenic signaling pathways in GBM are key aspects of GBM heterogeneity that present unique therapeutic challenges.

Table 1. Gene expression profiles in different regions of GBM tumors. The overview of the GBM regions reveals distinct patterns and enrichment of specific molecular profiles. The enriched gene profiles were analyzed during the Ivy Glioblastoma Atlas Project.

Tumor Region	Leading Edge and Infiltrating Tumor	Perinecrotic Zone	Pseudopalisading around Necrosis	Hyperplastic Blood Vessels in Cellular Tumor	Microvascular Proliferation
Top 10 Gene Expression Profile	VSNL1	PI3	IL8	COL3A1	ESM1
	CCK	IL8	VEGFA	LOC100506027	COL3A1
	SNAP25	CCL20	HILPDA	LUM	IBSP
	GABRA1	SLPI	NDRG1	COL1A1	CRIP1
	CRYM	SAA1	ADM	ACTG2	LOC100506027
	GNG3	PTX3	CA9	ESM1	HIGD1B
	SYT1	SAA2	CA12	ACTA2	RGS5
	NEFL	TREM1	ANGPTL4	COL6A3	ITGA1
	SYNPR	CHI3L1	HK2	COL1A2	OR51E1
	GABRA2	MMP7	CHI3L1	DCN	MMP9

Molecular interactions between tumor cells and non-tumor cells within the GBM tumor microenvironment (TME) add further complexity to intra-tumoral heterogeneity. Fortunately, the Ivy Glioblastoma Atlas Project (<https://glioblastoma.alleninstitute.org/>, accessed on 22 May 2024) made significant contributions toward understanding the genetic landscape in GBM from a regional perspective (Table 1). Biopsy samples were obtained using image-guided investigation of MRI-distinct regions in GBM, and the tissue was subjected to bulk RNA sequencing (RNA-seq). There were marked variations and significant regional heterogeneity based on the top 10 gene expression profiles (Table 1). Although the bulk tumor data were quite valuable, molecular details at the cellular level are more informative of intra-tumoral heterogeneity. Recent advances in single-cell RNA sequencing (scRNA-seq) have bridged the gap between the molecular profiling features of a bulk tumor and individual tumor cells. For instance, within the bulk tumor, there are variations in individual tumor cell gene expression and clustering, leading to heterogeneity in the GBM molecular subtype profiles of individual tumor cells with implications for therapeutic resistance [27]. Furthermore, scRNA-seq investigations have implicated the TME as a malignant facilitator of GBM through reprogramming mechanisms involving hypoxia [62], immunosuppression [63,64], MES reprogramming [65,66], and cellular metabolism [67,68]. Most recently, the emergence of spatial transcriptomics has permitted a deeper investigation of cellular interactions within the TME and optimal delineation of cellular niches within the tumor [69–71]. In a very recent study, Greenwald et al. defined GBM cellular states and uncovered their organization through approaches combining spatial transcriptomics, spatial proteomics, and computational analysis [72]. Their findings indicated that GBM tumors contain both disorganized and structured regions, whereby the organized regions were associated with an abundance of MES-hypoxic cancer cells that extended beyond what could be observed in histopathology.

The clonal evolution of GSCs and non-GSC populations and subsequent interactions with the tumor microenvironment (TME) contribute to heterogeneity. GSCs are constantly in a state of equilibrium toward differentiation into non-GSC populations versus the maintenance of stemness. Stemness hierarchical plasticity is the basis for initiating the recurrent tumor after cytotoxic therapy. In terms of cellular architecture heterogeneity, GSC subpopulations can be classified as oligodendrocyte progenitor cells, neural progenitor cells, astrocyte-like cells, or mesenchymal-like cells [73,74]. It is now apparent that *IDH* mutation status influences both the GSC proliferation state and cellular architecture [75]. For instance, the GSCs in *IDH*-mutant tumors are in a non-proliferative state compared

to GSCs in *IDH*-wild-type tumors where GSCs are highly proliferative. Furthermore, while *IDH*-mutant and *IDH*-wild-type tumors consist of mixed GSC subpopulations, the proliferating mesenchymal-like cells are most commonly associated with *IDH*-wild-type GBM [75].

Further insights into the molecular inter-tumoral and intra-tumoral heterogeneities of GSCs have emerged secondary to large-scale genomic and RNA sequencing investigations, that reveal GBM segregation into distinct survival prognostic molecular subtypes [76,77]. Using a combination of gene expression, mutational, and copy number analysis, Verhaak et al. subsequently stratified GBM into the following four distinct molecular subtypes reflecting inter-tumoral heterogeneity: proneural (PN), mesenchymal (MES), neural (NL), and classical (CL) [51]. PN tumors are often enriched in oligodendrocytic signature, have the best prognosis, and are characterized by mutations in *PDGFRA* and *IDH1/2* [51]. MES subtype tumors have a strong astrocytic signature, have the worst prognosis, and are genetically characterized by *NF1* mutations [51]. The classical subtype has an astrocytic signature as well but is characterized by *EGFR* aberrations [51]. The neural subtype has both astrocytic and oligodendrocytic signatures and is characterized by neuronal gene expressions [51]. Although the molecular subtypes in GBM have been identified based on individual tumor analysis, it is now evident from the stereotactic surgery investigation of different GBM regions in a single patient that more than one subtype can exist within the same tumor [78]. Intra-tumoral heterogeneity in GBM molecular subtypes has significant clinical implications with respect to therapeutic response and prognosis.

A unique advantage of the classification of GBM into distinct molecular subtypes is the association of genetic heterogeneity with therapeutic resistance and tumor recurrence. For instance, the single-cell RNA sequencing (scRNA-Seq) of GBM further reveals the impact of intra-tumoral heterogeneity in molecular subtypes on GBM survival [27]. It became evident that all GBM tumors have PN subpopulations and that it was the variance of PN subpopulations relative to the other molecular subtypes that impacts survival [27]. MES subpopulations are highly resistant to therapy and confer dismal survival compared to other subtypes. TCGA dataset analysis revealed *NF1* mutations and NF- κ B signaling aberrations as facilitators of the MES subtype [79]. Furthermore, TNF- α /NF- κ B signaling drives radiation resistance in GBM through the PN to MES transition of GBM stem cells [80]. Similarly, the induction of TGF- β 2 through the dephosphorylation of OLIG2 facilitates MES transition [81]. Hence, within the context of molecular intra-tumoral heterogeneity, MES proclivity significantly impacts survival and contributes to variations in clinical outcomes.

4. MES Reprogramming

MES reprogramming is a cellular process during which cancer cells acquire enhanced migratory and invasive characteristics contributing to malignant transformation and propagation [82]. MES reprogramming is driven by signaling networks involving transcriptional factors and downstream effectors, and reprogramming is often the aftermath of interactions between cancer cells and the TME or therapeutic exposure [82]. Although MES reprogramming was traditionally considered as a phenomenon mainly unique to epithelial cancers, the MES state of GBM has been identified through molecular clustering whereby *NF1* loss appears to be a consistent genetic lesion [51]. There is mounting evidence that therapeutic resistance and recurrence in GBM are associated with enhanced MES phenotype reprogramming [83–85]. For instance, detailed analyses of recurrent GBMs have uncovered evidence of molecular subtype transitions as the basis for chemotherapy and radiotherapy resistance [77,85–88]. PN towards MES reprogramming represents the most common molecular subtype transition whereby PN genes are down-regulated and MES genes are upregulated [80,89–91]. MES and PN preclinical genetic models of GBM driven by *NF1* loss and *PDGF*B overexpression, respectively, demonstrate differential responses to radiation (RT) and TMZ whereby the *PDGF*B overexpression phenotype is more sensitive compared to the *NF1* loss phenotype [92]. Interestingly, therapy-resistant GBMs have an MES-like phenotype, while therapy-sensitive GBMs have a PN-like phenotype [85]. Given

the profound negative impact of MES reprogramming on GBM outcomes, there is urgency and renewed emphasis on identifying drivers of MES reprogramming with the hopes of developing novel GBM therapies.

Besides the acquisition of invasive and migratory phenotypes, MES reprogramming appears to also activate unique metabolic programs to support demands associated with the aforementioned phenotypes [82]. Thus far, the detailed mechanism of how metabolic alteration synergizes with MES reprogramming is poorly understood in GBM. However, there are some studies that have reported the correlation between metabolic alteration and MES reprogramming in GBM. For instance, Su et al. demonstrated that metabolic and subsequent MES reprogramming in GBM occurs through the TGF β 1-mediated upregulation of NADPH oxidases 4 (NOX4) and reactive oxygen species (ROS), leading to downstream overexpression and nuclear accumulation of hypoxia-inducible factor 1 α (HIF-1 α) [93]. Utilizing a combination of patient GBM xenografts and patient GBM tissues, Talasila et al. analyzed gene expression changes associated with invasive and angiogenic phenotypes in GBM [94]. They observed an angiogenic switch that was highly correlated with MES programming whereby angiogenic xenografts employed higher rates of glycolysis compared with invasive xenografts. They also noted that MES reprogramming was associated with angiogenic switch through the upregulation of transcriptional factors BHLHE40, CEBEP, and STAT3, which employ higher rates of glycolysis. Lastly, malic enzyme (ME2), an enzyme that catalyzes the formation of pyruvate from malic acid, was found to be highly expressed in GBM and its expression was positively correlated with MES reprogramming through upregulation of MES gene markers and downregulation of PN gene markers [95]. ME2 mediated metabolic reprogramming through inhibition of ROS and AMPK phosphorylation and subsequent facilitation of SREBP-1 nuclear localization, leading to ACSS2 lipogenesis.

4.1. Treatment-Induced MES Reprogramming and Clinical Relevance

One of the most significant challenges in the treatment of GBM is the limited durability of clinical response. As already alluded to, heterogeneity in molecular subtypes, as well as a propensity for clonal evolution toward a more aggressive molecular subtype, have therapeutic–prognostic implications. GBM treatment can reprogram GSCs toward an aggressive MES phenotype, leading to enhanced stemness, invasion, and therapeutic resistance. In particular, treatment-induced MES reprogramming is a significant contributor to GBM therapeutic refractoriness to chemotherapy and radiotherapy [79,80,86,96–98]. Both radiation therapy and chemotherapy induce MES reprogramming in GBM preclinically and clinically. In order to overcome the challenge of MES reprogramming, a detailed understanding of molecular mechanisms associated with the MES status of GSCs is necessary.

In an attempt to decipher molecular drivers of MES reprogramming in GSCs, Bhat et al. identified a genetic signature associated with MES transition, radiation resistance, and poor GBM outcomes mediated through NF- κ B signaling pathway activation [80]. NF- κ B signaling activation reprogrammed GSCs toward an MES phenotype that was highly resistant to radiation resistance through upregulation of CD44 [80]. Paradoxically, radiation therapy has been implicated as a propagator of the MES reprogramming of GBM through the activation of critical MES regulators and signature genes [86,96]. In PN GBM mouse models, radiation treatment induced PN to MES reprogramming both genetically and phenotypically [86]. Furthermore, radiation-mediated MES GBMs are generally more invasive and resistant to TMZ [96]. It is now recognized that the radiation-induced upregulation of TGF- β , VEGF, and PDGF promotes tumor invasion and resistance associated with MES reprogramming [99,100]. New insights into the impact of GBM radiation therapy on brain-invasive GBM cells have provided further enlightenment on transcription programs of MES reprogramming in GBM with potential implications for treatment outcomes [97]. The brain-invasive front of GBM represents a region where the safe resection of tumors is not feasible because tumor cells are highly infiltrated into normal brain tissue. Minata and colleagues recently identified two subpopulations of GSCs within the invasive front of GBM patients,

consisting of a CD133+ PN subpopulation and a CD109+ MES subpopulation [97]. Upon exposure to ionizing radiation, CD133+ PN GSCs transitioned to CD109+ MES GSCs, suggesting that radiation induces the expression of CD109 [97]. Mechanistically, the radiation-induced expression of CD109 in GSCs leads to downstream activation of the TAZ/YAP axis, resulting in MES reprogramming, brain invasion, and radiation resistance [97]. Hence, CD109 could serve as a therapeutic target for radiation-induced MES reprogramming in GBM. Approaches to targeting radiation-induced reprogramming have focused on master transcriptional regulators such as STAT3 [96,101] and NF- κ B [102] pathways. Targeting STAT3 either through a small molecule inhibitor of survivin, YM155 [101] or through the upstream blockade of STAT3 using JAK2 inhibitors (AZD1480 or ruxolitinib) [96] significantly enhanced radiation sensitivity and prevented MES reprogramming. Recently, it was reported that activation of adhesion G-protein-coupled receptor G1 (GPR56/ADGRG1) could abrogate NF- κ B pathway-mediated MES reprogramming in GBM [102].

MES reprogramming is equally a challenge to GBM alkylator chemotherapy where transcription factors such as the forkhead box protein O1 (FOXO1) drive MES resistance reprogramming in GBM to alkylators [103]. TMZ is generally the first-line therapy in GBM administered concurrently with radiotherapy followed by adjuvant TMZ. Given its DNA alkylating mechanism, TMZ treatment leads to a hypermutated and MES phenotype, especially upon tumor recurrence, and further studies evaluating the genetic and phenotypic changes associated with the evolution of TMZ resistance in GBM interestingly revealed the acquisition of an MES gene signature as part of the evolution of GBM cells toward TMZ resistance [104–107]. In GBM, there are sub-populations of proliferative as well as quiescent GSCs. Not surprisingly, quiescent GSCs are highly refractory to anti-proliferative therapy with TMZ and harbor a very strong TGF- β and HIF1 α transgene MES signature [106]. Recent findings have revealed that several key transcriptional pathways play crucial roles in MES reprogramming and TMZ resistance. For instance, FOXO1 affects multiple MES marker genes' expression and further positively induces TMZ and CDDP (Cisplatin) resistance [103], while STAT3 and NF- κ B could induce an immunosuppressive environment associated with TAMs dependent on mTOR activity [108].

Beyond alkylating chemotherapy agents, anti-angiogenic agents have been employed as second-line agents in GBM therapy but without any significant impact on overall survival [109–111]. Emerging data have implicated anti-angiogenic therapy in promoting GBM tumor hypoxia and MES reprogramming [83,84,112]. Hence, anti-angiogenic therapy failures are often associated with markedly invasive and resistant GBM at recurrence. The MES reprogramming propensity of standard first-line and second-line GBM therapies significantly underscores the urgent need for new treatments that could either prevent or treat MES reprogramming.

4.2. Heterogenous Tumor Microenvironment

The GBM tumor microenvironment (TME) is another major contributor to malignant reprogramming in GBM (Figure 2). Cellular and molecular heterogeneities are highly featured within the TME in GBM (Table 1). Furthermore, distinct histological and MRI-defined regions in GBM with unique cellular compositions and transcriptional programs contribute to intra-tumoral heterogeneity [113] (Table 1). The well-recognized MRI distinct regions include the central necrotic zone, the tumor-enhancing zone, and the peri-tumoral flair or edema region [114–116]. The central necrotic region is highly hypoxic and hypocellular with respect to tumor cells, while the tumor-enhancing region is highly angiogenic and hypercellular [114–116]. The peri-tumoral flair region harbors brain-invasive GBM cells. Furthermore, histopathologic correlates of the TME include perinecrotic/pseudopalisading regions, the tumor core, and brain-invasive regions. Additional insights into the unique transcriptional programs within each TME niche have emerged through meticulous assessment of laser-microdissected GBM patient tissues [117]. The perinecrotic/pseudopalisading regions of GBM are highly MES and are characterized by HIF1 α signaling, TNF- α signaling, and immune response gene enrichment signatures [117]. Not surprisingly, hypoxia

is a crucial feature of the perinecrotic/pseudopalisading regions of GBM, and a critical facilitator of both GSC proliferation and angiogenesis [118,119]. While the complete mechanistic underpinnings of the hypoxia-mediated malignant reprogramming of GBM are not fully elucidated, there is mounting evidence that the TME is a critical facilitator. One proposed mechanism of the hypoxia-mediated malignant reprogramming of GBM via the direct activation of pro-angiogenic genes and the subsequent recruitment of inflammatory cells [118,120]. HIF1 α signaling secondary to hypoxia has a significant impact on GBM cells. For instance, it has been demonstrated that activation of the HIF1 α -ZEB1 axis contributes to GBM invasion and MES reprogramming [121]. Furthermore, genetic silencing or pharmacological inhibition of HIF1 α effectively reversed hypoxia-mediated MES reprogramming [121]. Another postulated mechanism of hypoxia-mediated MES reprogramming involves the EPHB2-HIF2 α -paxillin signaling axis [122]. HIF2 α is required for the stabilization of the tyrosine kinase receptor (TKR) EPHB2 and promotes MES reprogramming by phosphorylating paxillin and focal adhesion kinase (FAK) [122]. Hence, HIF1 α - and HIF2 α -related mechanisms have MES reprogramming implications for GBM cells within the hypoxic tumor microenvironment. Interestingly, it is now recognized that interactions between normal glial cells with tumor cells can create hypoxia adaptation synergies for tumor cells. For instance, it is postulated that astrocytes within the hypoxic microenvironment release the cytokine CCL20 and upregulate HIF1 α in an NF- κ B signaling-dependent manner, thereby creating hypoxia adaptation for GBM [123]. Interestingly, the MES reprogramming of GBM cells shares similar genetic signatures with astrocyte reactivity [124]. Collectively, these observations indicate that TME factors cooperate with each other to form interaction networks that promote MES reprogramming in GBM (Figure 2).




Figure 2. The impact of the GBM tumor microenvironment on MES reprogramming. Representative mechanisms underlying MES reprogramming in the GBM tumor microenvironment. Different cell types from the GBM tumor microenvironment including T cells, tumor-associated macrophages (TAMs), and microglia can interact with GBM tumor cells and further impact GBM cell MES reprogramming. Such MES reprogramming can be demonstrated by specific gene markers including *CD44*, *YKL40*, *TIMP1*, *SERPINE1*, and *TGFB1*.

Tumor-associated immune cells represent a critical component of the TME. There is mounting evidence that immune-mediated mechanisms are associated with MES reprogramming [80,125,126]. MES subtype GBMs are highly characterized by pro-inflammatory

and immunosuppressive genetic profiles [125–129]. Furthermore, tumor infiltrative T lymphocytes are highly represented in MES GBM compared to other GBM molecular subtypes, confirming an immune propensity in MES reprogramming [125,126,130,131]. Recent findings point out that MES-like states may be associated with T cell activation [132]. It is now apparent that of all T cell types, CD8⁺ T cells are the most represented in MES GBM [127]. Besides lymphoid infiltration, there is mounting evidence of myeloid infiltration into the GBM TME [133,134]. Chemokines and cytokines secreted by GBM cells within the hypoxic niche can activate and recruit TAMs in the TME [135]. MES master transcription regulators such as STAT3 and NF- κ B have been implicated as contributors to the immunosuppressive environment associated with TAMs [108]. TAMs as well as microglia can promote hypoxia-induced neovascularization through the release of VEGF and CXC-chemokine ligand 2 (CXCL2) into the TME [136]. TAMs and microglia also express TNF- α , TGF- β , and MMP9, which facilitate the MES reprogramming of GBM cells [80,128,137]. Specifically, the secretion of extracellular matrix remodeling factors along with pro-angiogenic and anti-inflammatory cytokines contributes to an aggressive MES tumor phenotype. Hence, MES GBMs are most commonly associated with macrophage/microglia infiltration and necrosis [51,77,138]. Collectively, interactions between the immune components of TME and GBM cells enhance the adaptive fitness of tumor cells within the hypoxic niche through MES reprogramming (Figure 2). Such interactions can provide valuable insights into the complex cellular and molecular interplay with the TME and may also yield innovative therapeutic targets [139,140].

4.3. Key Regulators, Pathways, and Clinical Targets in MES Reprogramming

A deeper understanding of the mechanistic underpinnings related to transcriptional regulators of MES reprogramming in GBM is essential in addressing the unmet need for novel GBM therapeutics (Figure 3). The master regulator of the MES state has been extensively studied in several cancers, including GBM, whereby NF- κ B has emerged as a critical regulator of the malignant reprogramming of cancer stem cells [141,142] (Figure 3). NF- κ B impacts both tumor cells and the TME. In tumor cells, NF- κ B promotes the expression of MES-like markers, while within the TME, NF- κ B induces the expression of various pro-inflammatory genes, including those encoding cytokines and chemokines [125,143,144]. The combination of MES expression and a highly proinflammatory TME accounts for the therapeutic resistance of GBM. Besides the direct induction of MES markers in GBM, NF- κ B signaling could indirectly mediate MES reprogramming through crosstalk with other regulators including STAT3 and HIF1 α [123,145]. Similar to NF- κ B, STAT3 exerts transcriptional regulation of both GBM cells and the TME. In GBM cells, co-transcriptional synergistic activation of both STAT3 and C/EBP β is necessary for MES transformation [146] (Figure 3). As master regulators of MES reprogramming, activation of STAT3 and C/EBP β induced the transcription of MES genes in GSCs, while suppression of STAT3 and C/EBP β abrogated the MES gene profile and phenotype. Furthermore, within the GBM TME, activation of both STAT3 and C/EBP β propagated tumor necrosis and hypoxia [79,138]. Moreover, as previously alluded to, TAMs are significantly abundant in MES GBM, and it now appears that the modulation of STAT3 transcriptional activity in TAMs is a basis for TAM-mediated MES reprogramming in GBM [137]. Besides TAMs, microglia represent another important closely related TME component that modulates GBM cell transcriptional fate. Mechanistically, microglia facilitate TME immunosuppression, tumor immune evasion, and tumor MES transition through the mTOR-dependent regulation of STAT3 and NF- κ B [108]. Recently, TAZ, the transcriptional activator with PDZ-binding motif was identified as an MES-related network inducer, whose activity was correlated with GSC invasion and self-renewal (Figure 3). Mechanistically, TAZ forms a complex with the transcriptional enhanced associate domain (TEAD), thereby facilitating the recruitment of TAZ to MES gene promoters [147]. Similar to STAT3 and C/EBP β , TAZ activity promotes GBM tumor necrosis, which also propagates MES reprogramming and stemness [148]. TAZ can also impact MES reprogramming through its downstream interactions with the

Hippo signaling pathway through co-activation of the pathway with Yes-associated protein (YAP) [149]. Although the TAZ transcriptional program appears to be independent of that of STAT3-C/EBP β despite similarities to GBM tumor cell and TME impacts, both transcription programs intersect with NF- κ B. It was recently reported that the NF- κ B-mediated MES reprogramming and therapeutic resistance in GSCs occurred through the regulation of STAT3, C/EBP β , and TAZ [80,150]. Collectively, NF- κ B in cooperation with other regulators, serves as a critical master regulator of MES reprogramming within the TME in GBM.




Figure 3. Key factors impacting MES reprogramming. Schematic summary of the most important gene/protein regulators as well as biological events/interventions involved in GBM MES reprogramming. (1) Therapeutic treatment (TMZ, radiation, etc.): treatment can reprogram GSCs toward an aggressive MES phenotype, leading to enhanced stemness, invasion, and therapeutic resistance. (2) Hypoxic environment: a hypoxic TME can mediate malignant reprogramming of GBM through the direct activation of pro-angiogenic genes and recruitment of inflammatory cells. (3) Inflammatory-related cytokines: these cytokines along with the extracellular matrix contribute toward an aggressive MES tumor phenotype. (4) Epigenetic regulator (EZH2): EZH2-mediated histone methylation plays an important role in the regulation of the expression levels of multiple MES marker and regulator genes. (5) LncRNAs, and (6) miRNAs: these two kinds of non-coding RNAs contribute to GBM MES reprogramming through the regulation of key transcriptional factors, such as ZEB1. (7) Key signaling pathways (TGF- β , TNF- α , STAT3, NF- κ B, and TAZ/YAP) and (8) angiogenic factor signaling (VEGF): these key signaling pathways are the master regulator of malignancy, and they frequently interact/collaborate with the hypoxic TME and therapeutic treatment to promote MES reprogramming. (9) Some other key genes (BIRC3 and S100A4): these genes are also identified as the driver of MES reprogramming, through activation of key transcriptional factors including C/EBP β , TAZ, and STAT3.

The recent identification of several potential targetable molecular biomarkers of MES reprogramming has raised prospects for clinical translation. Our group identified an anti-apoptotic protein, BIRC3 (baculoviral IAP repeat containing 3), as a biomarker for MES GBM and a mediator of hypoxia-driven survival adaptation through HIF1 α signaling [151] (Figure 3). BIRC3 was previously reported as a novel driver of therapeutic resistance in

GBM [151,152]. The dual role of BIRC3 in apoptosis evasion and MES reprogramming renders BIRC3 a potential biomarker and therapeutic target for MES GBM that could synergize with cytotoxic chemotherapy. The enzyme transglutaminase 2 (TGM2) is another reported biomarker of the peri-necrotic hypoxic region of GBM [153]. TGM2 has been implicated as a driver of GSC MES reprogramming through the activation of key transcriptional factors including C/EBP β , TAZ, and STAT3, suggesting that it could be a potential therapeutic target for MES reprogramming [153]. Another reported MES biomarker and potential therapeutic target is S100A4, a gene encoding a small calcium-binding protein that interacts with other key regulators such as p53 [154]. S100A4 has been identified as a critical regulator of GSC self-renewal as well as a reporter of MES reprogramming through the downstream regulation of key transcriptional factors such as SNAIL2 and ZEB1 [154]. Furthermore, the neurotrophic factor prosaposin (PSAP), a conserved glycoprotein that promotes GBM migration/invasion and MES reprogramming via the TGF- β 1/SMAD signaling pathway, has been reported as a novel targetable MES biomarker [155] (Figure 3).

There is mounting evidence that the regulatory activities of certain long noncoding RNAs (lncRNAs) contribute to MES reprogramming in GBM through the upregulation of MES genetic markers and MES phenotypes. A novel lncRNA, TALNEC2, was recently reported to be highly expressed in GBM and identified as a regulator of cell proliferation and MES transformation [156]. Silencing of TALNEC2 successfully attenuates both GSC self-renewal and MES reprogramming, leading to radiation sensitivity both in vitro and in vivo [156]. Cooperative interactions between lncRNAs, microRNAs (miRNAs), and other key regulators of MES reprogramming such as the ZEB signaling axis exist in GBM [157,158]. For instance, the lncRNA LINC00511 regulates and promotes MES reprogramming in GBM through the LINC00511/miR-524-5p/ZEB1 signaling axis [157]. Furthermore, there is supportive evidence that through TGF- β activation, ZEB1 could also upregulate another lncRNA, LINC00645, to mediate MES reprogramming through the LINC00645/miR-205-3p/ZEB1 signaling axis [158]. Interestingly, lncRNAs can also suppress MES reprogramming. lncRNA LINC00599 functions as a tumor suppressor in GBM, whereby the expression of LINC00599 significantly attenuates GBM MES reprogramming and tumor aggressiveness [159].

Besides lncRNAs, microRNAs have been reported to play an important role in modulating MES reprogramming in GBM. For instance, miR-181c was found to be downregulated in GBM, and the overexpression of miR-181c inhibits TGF- β signaling and further suppresses tumor cell invasion and MES reprogramming [160]. Specifically, miR-181c inhibits TGF- β signaling by downregulating TGFBR1, TGFBR2, and TGFBRAP1 expressions. Recently, Zhang et al. analyzed multiple GBM databases including the TCGA, GSE16011, and Rembrandt and reported that miR-95 and miR-223 have opposing modulatory impacts on MES reprogramming in GBM [161]. Overexpression of miR-95 suppressed MES reprogramming while overexpression of miR-223 facilitated MES reprogramming. The functional correlation between MES reprogramming and miR-223 was further confirmed in a study by Huang et al., in which they showed that the inhibition of the miR-223-PAX6 axis suppressed cell invasion and improved chemotherapy sensitivity [162]. MiR-96 was recently identified as a tumor suppressor and potential therapeutic agent that antagonizes MES reprogramming in GBM through the downregulation of AEG-1 [163]. MiR-101-3p was also found to be a negative regulator of MES reprogramming through the inhibition of TRIM44 signaling [164].

Epigenetic mechanisms have also been implicated in malignant reprogramming in GBM [165–168]. Interestingly, the inhibition of HDAC6, a histone deacetylase was found to attenuate and also reverse MES signature gene reprogramming in GBM [165]. Histone methyltransferases represent another class of histone modifiers that may play a role in GBM MES reprogramming through the promoter methylation silencing of target genes. For instance, the suppression of H3K27 methylation by enhancer of zeste homolog 2 (EZH2), a histone lysine N-methyltransferase enzyme, reverses MES reprogramming through the upregulation of EZH2 target genes and the downregulation of MES markers [168]

(Figure 3). Furthermore, interactions between downstream miRNA targets of EZH2 and key master regulators of MES reprogramming such as TGF- β signaling in GBM have been reported [166]. In particular, EZH2 has been identified as a regulator of the miR-490-3p/TGIF2/TGFBR1 signaling axis [166]. Collectively, histone modifications represent a common phenomenon and may confer therapeutic vulnerability for targeting malignant reprogramming in GBM.

It is worth noting that there are ongoing efforts to identify and target novel critical drivers of MES reprogramming. Understanding and targeting the mechanistic underpinnings of key MES drivers are essential for improving GBM therapeutic outcomes.

4.4. Recent and Potential Therapies Targeting MES Reprogramming

MES reprogramming is a very complicated and challenging phenomenon in GBM with an unmet need for innovative therapies. Currently, there are no effective clinical therapies to treat or prevent MES reprogramming. However, several promising preclinical and clinical agents have been explored and repurposed as anti-MES therapies. Ideally, these agents should have excellent blood–brain barrier penetrance and synergize with standard GBM therapy.

Recently, paeoniflorin, a natural anti-cancer compound that has been widely studied both in the preclinical and clinical settings, was found to inhibit MES reprogramming and angiogenesis in GBM [169]. Paeoniflorin was first identified as an anti-inflammatory and anti-oxidative drug and later noted to exhibit anti-cancer effects through the induction of apoptosis. In this study, it was demonstrated that paeoniflorin can activate autophagy, promote c-Met degradation via K63-linked polyubiquitination, and further inhibit MES reprogramming and angiogenesis in GBM.

As previously mentioned, TGF- β is one of the key growth factors that triggers MES reprogramming and angiogenesis in many cancers including GBM. Several anti-TGF- β pharmacologic targeting strategies have been evaluated. Pirfenidone, an anti-fibrosis FDA-approved agent, was reported to inhibit TGF- β expression in malignant glioma cells [170]. Similarly, quetiapine, an FDA-approved anti-psychotic agent, was also reported to inhibit MES reprogramming in a RANKL-TGF- β dependent manner [171]. GBM tumor cells can secrete RANKL into TME and increase tumor cell motility to surrounding non-malignant cells, such as astrocytes, and further induce these surrounding cells to secrete TGF- β which in turn reprograms GBM cells to the MES-like invasive type [171]. Thus, combination treatment with quetiapine and pirfenidone may undermine RANKL/TGF- β signaling and interaction between GBM cells and surrounding cells, which can further suppress MES reprogramming [170,171]. Another FDA-approved agent with anti-TGF- β activity is the anti-diabetic agent metformin [172,173]. Metformin was found to inhibit both MES reprogramming and stem-like properties in GBM through TGF- β and AKT/mTOR pathways [174,175]. Given the critical role of TGF- β in MES reprogramming, synergies between standard GBM therapies and the inhibition of TGF- β through pirfenidone, quetiapine, and metformin merits further investigation.

5. Conclusions

Despite significant advances in and enlightenment on the genetic and epigenetic landscapes of GBM, there has been limited progress in improving outcomes for patients afflicted with this very lethal cancer. The interplay between the GSC tumor niche and the TME has emerged as the critical determinant for the therapeutic refractoriness of GBM. Hence, several critical challenges related to the tumor niche as well as the TME niche have to be simultaneously addressed to positively impact therapeutic outcomes. Within the tumor niche, the cellular and molecular heterogeneity of GSC subpopulations modulate clonal adaptation to therapy, leading to malignant reprogramming and therapeutic resistance. Furthermore, the immunosuppressive cellular components of the TME perpetuate malignant reprogramming of the GSC niche. Therefore, the development of therapeutic strategies that prevent clonal adaptation within the GSC niche is highly essential.

In this review, we have presented an overview of potential therapeutic targets associated with signaling nodes and master regulators of malignant reprogramming. Methodical assessment of potential therapeutic targets could be accomplished through window-of-opportunity clinical trials in recurrent GBM patients undergoing standard-of-care salvage surgery, whereby resected tumor tissue can be analyzed for both drug penetrance and drug target engagement. Hence, developing and establishing the brain-penetrance profile of novel anti-malignant reprogramming therapies should be the objective of future efforts.

Author Contributions: A.B.E. designed the study; Q.W. and A.B.E. wrote the manuscript; A.E.B. and R.J.M. reviewed and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The study was supported by the Moffitt Cancer Center Foundation; the National Institute of Neurological Disorders and Stroke support grants 1R21NS120800 and 1R01NS135220; and the National Cancer Institute support grant 1R21CA264635.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

BIRC3	Baculoviral IAP repeat containing 3
CXCL2	CXC-chemokine ligand 2
DNMT	DNA methyltransferase
EMT	Epithelial–mesenchymal transition
EZH2	Enhancer of zeste homolog
FAK	Focal adhesion kinase
FOXO1	Forkhead box protein O1
GBM	Glioblastoma
GSC	GBM stem cell
HDAC	Histone deacetylase
IDH	Isocitrate dehydrogenase
lncRNA	Long Non-Coding RNAs
MM9	Matrix metalloproteinase 9
MES	Mesenchymal
MGMT	O-6-methylguanine-DNA methyltransferase
PN	Proneural
RANKL	Receptor activator of nuclear factor kappa beta
RTKs	Receptor tyrosine kinases
scRNA-Seq	Single-cell RNA sequencing
STAT3	Signal transducer and activator of transcription 3
TAMs	Tumor-associated macrophages
TAZ	Transcriptional activator with PDZ-binding motif
TGM2	The enzyme transglutaminase 2
TME	Tumor microenvironment
TMZ	Temozolomide
YAP	Yes-associated protein

References

1. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* **2007**, *114*, 97–109. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
2. Ostrom, Q.T.; Gittleman, H.; Farah, P.; Ondracek, A.; Chen, Y.; Wolinsky, Y.; Stroup, N.E.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. *Neuro-Oncology* **2013**, *15* (Suppl. S2), ii1–ii56. [[CrossRef](#)] [[PubMed](#)]

3. Tran, B.; Rosenthal, M.A. Survival comparison between glioblastoma multiforme and other incurable cancers. *J. Clin. Neurosci.* **2010**, *17*, 417–421. [[CrossRef](#)] [[PubMed](#)]
4. Thakkar, J.P.; Dolecek, T.A.; Horbinski, C.; Ostrom, Q.T.; Lightner, D.D.; Barnholtz-Sloan, J.S.; Villano, J.L. Epidemiologic and molecular prognostic review of glioblastoma. *Cancer Epidemiol. Biomark. Prev.* **2014**, *23*, 1985–1996. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
5. Bleeker, F.E.; Atai, N.A.; Lamba, S.; Jonker, A.; Rijkeboer, D.; Bosch, K.S.; Tigchelaar, W.; Troost, D.; Vandertop, W.P.; Bardelli, A.; et al. The prognostic *IDH1*^{R132} mutation is associated with reduced NADP⁺-dependent IDH activity in glioblastoma. *Acta Neuropathol.* **2010**, *119*, 487–494. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
6. Brennan, C.W.; Verhaak, R.G.; McKenna, A.; Campos, B.; Nounshmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. *Cell* **2013**, *155*, 462–477. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
7. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N. Engl. J. Med.* **2005**, *352*, 997–1003. [[CrossRef](#)] [[PubMed](#)]
8. Li, Q.; Guo, J.; Wang, W.; Wang, D. Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma. *Oncol. Lett.* **2017**, *14*, 229–233. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
9. Rivera, A.L.; Pelloso, C.E.; Gilbert, M.R.; Colman, H.; De La Cruz, C.; Sulman, E.P.; Bekele, B.N.; Aldape, K.D. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. *Neuro-Oncology* **2010**, *12*, 116–121. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
10. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 mutations in gliomas. *N. Engl. J. Med.* **2009**, *360*, 765–773. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
11. Taylor, O.G.; Brzozowski, J.S.; Skelding, K.A. Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets. *Front. Oncol.* **2019**, *9*, 963. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
12. Omuro, A.; Vlahovic, G.; Lim, M.; Sahebjam, S.; Baehring, J.; Cloughesy, T.; Voloschin, A.; Ramkissoon, S.H.; Ligon, K.L.; Latek, R.; et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. *Neuro-Oncology* **2018**, *20*, 674–686. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
13. Reardon, D.A.; Brandes, A.A.; Omuro, A.; Mulholland, P.; Lim, M.; Wick, A.; Baehring, J.; Ahluwalia, M.S.; Roth, P.; Bähr, O.; et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. *JAMA Oncol.* **2020**, *6*, 1003–1010. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
14. Sampson, J.H.; Aldape, K.D.; Archer, G.E.; Coan, A.; Desjardins, A.; Friedman, A.H.; Friedman, H.S.; Gilbert, M.R.; Herndon, J.E.; McLendon, R.E.; et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. *Neuro-Oncology* **2011**, *13*, 324–333. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
15. Schuster, J.; Lai, R.K.; Recht, L.D.; Reardon, D.A.; Paleologos, N.A.; Groves, M.D.; Mrugala, M.M.; Jensen, R.; Baehring, J.M.; Sloan, A.; et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study. *Neuro-Oncology* **2015**, *17*, 854–861. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
16. Weller, M.; Butowski, N.; Tran, D.D.; Recht, L.D.; Lim, M.; Hirte, H.; Ashby, L.; Mechtler, L.; Goldlust, S.A.; Iwamoto, F.; et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. *Lancet. Oncol.* **2017**, *18*, 1373–1385. [[CrossRef](#)] [[PubMed](#)]
17. Chuntova, P.; Chow, F.; Watchmaker, P.B.; Galvez, M.; Heimberger, A.B.; Newell, E.W.; Diaz, A.; DePinho, R.A.; Li, M.O.; Wherry, E.J.; et al. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. *Neuro-Oncology* **2021**, *23*, 356–375. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
18. Cloughesy, T.F.; Mochizuki, A.Y.; Orpilla, J.R.; Hugo, W.; Lee, A.H.; Davidson, T.B.; Wang, A.C.; Ellingson, B.M.; Rytlewski, J.A.; Sanders, C.M.; et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. *Nat. Med.* **2019**, *25*, 477–486. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
19. Corso, C.D.; Bindra, R.S. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. *Semin. Radiat. Oncol.* **2016**, *26*, 281–298. [[CrossRef](#)] [[PubMed](#)]
20. McGranahan, T.; Therkelsen, K.E.; Ahmad, S.; Nagpal, S. Current State of Immunotherapy for Treatment of Glioblastoma. *Curr. Treat. Options Oncol.* **2019**, *20*, 24. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
21. Westphal, M.; Maire, C.L.; Lamszus, K. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise. *CNS Drugs* **2017**, *31*, 723–735. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
22. Chongsathidkiet, P.; Jackson, C.; Koyama, S.; Loebel, F.; Cui, X.; Farber, S.H.; Woroniecka, K.; Elsamacicy, A.A.; Dechant, C.A.; Kemeny, H.R.; et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. *Nat. Med.* **2018**, *24*, 1459–1468. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
23. Hodges, T.R.; Ott, M.; Xiu, J.; Gatalica, Z.; Swensen, J.; Zhou, S.; Huse, J.T.; de Groot, J.; Li, S.; Overwijk, W.W.; et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: Implications for immune checkpoint immunotherapy. *Neuro-Oncology* **2017**, *19*, 1047–1057. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

24. Indraccolo, S.; Lombardi, G.; Fassan, M.; Pasqualini, L.; Giunco, S.; Marcato, R.; Gasparini, A.; Candiottto, C.; Nalio, S.; Fiduccia, P.; et al. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. *Clin. Cancer Res.* **2019**, *25*, 1828–1837. [[CrossRef](#)] [[PubMed](#)]
25. Jackson, C.M.; Choi, J.; Lim, M. Mechanisms of immunotherapy resistance: Lessons from glioblastoma. *Nat. Immunol.* **2019**, *20*, 1100–1109. [[CrossRef](#)] [[PubMed](#)]
26. Kennedy, B.C.; Maier, L.M.; D’Amico, R.; Mandigo, C.E.; Fontana, E.J.; Waziri, A.; Assanah, M.C.; Canoll, P.; Anderson, R.C.; Anderson, D.E.; et al. Dynamics of central and peripheral immunomodulation in a murine glioma model. *BMC Immunol.* **2009**, *10*, 11. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
27. Patel, A.P.; Tirosh, I.; Trombetta, J.J.; Shalek, A.K.; Gillespie, S.M.; Wakimoto, H.; Cahill, D.P.; Nahed, B.V.; Curry, W.T.; Martuza, R.L.; et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **2014**, *344*, 1396–1401. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
28. Cifarelli, C.P.; Jacques, A.; Bobko, A. Heterogeneity of radiation response in mesenchymal subtype glioblastoma: Molecular profiling and reactive oxygen species generation. *J. Neurooncol.* **2021**, *152*, 245–255. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
29. Kim, Y.; Varn, F.S.; Park, S.H.; Yoon, B.W.; Park, H.R.; Lee, C.; Verhaak, R.G.W.; Paek, S.H. Perspective of mesenchymal transformation in glioblastoma. *Acta Neuropathol. Commun.* **2021**, *9*, 50. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
30. Thomas, J.G.; Parker Kerrigan, B.C.; Hossain, A.; Gumin, J.; Shinojima, N.; Nwajei, F.; Ezhilarasan, R.; Love, P.; Sulman, E.P.; Lang, F.F. Ionizing radiation augments glioma tropism of mesenchymal stem cells. *J. Neurosurg.* **2018**, *128*, 287–295. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
31. Bradshaw, A.; Wickremsekera, A.; Tan, S.T.; Peng, L.; Davis, P.F.; Itinteang, T. Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. *Front. Surg.* **2016**, *3*, 21. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
32. Mitchell, K.; Troike, K.; Silver, D.J.; Lathia, J.D. The evolution of the cancer stem cell state in glioblastoma: Emerging insights into the next generation of functional interactions. *Neuro-Oncology* **2021**, *23*, 199–213. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
33. Lee, J.H.; Lee, J.E.; Kahng, J.Y.; Kim, S.H.; Park, J.S.; Yoon, S.J.; Um, J.Y.; Kim, W.K.; Lee, J.K.; Park, J.; et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. *Nature* **2018**, *560*, 243–247. [[CrossRef](#)] [[PubMed](#)]
34. Vescovi, A.L.; Galli, R.; Reynolds, B.A. Brain tumour stem cells. *Nat. Rev. Cancer* **2006**, *6*, 425–436. [[CrossRef](#)] [[PubMed](#)]
35. Iacopino, F.; Angelucci, C.; Piacentini, R.; Biamonte, F.; Mangiola, A.; Maira, G.; Grassi, C.; Sica, G. Isolation of cancer stem cells from three human glioblastoma cell lines: Characterization of two selected clones. *PLoS ONE* **2014**, *9*, e105166. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
36. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. *Nature* **2004**, *432*, 396–401. [[CrossRef](#)] [[PubMed](#)]
37. Pointer, K.B.; Clark, P.A.; Zorniak, M.; Alrfaei, B.M.; Kuo, J.S. Glioblastoma cancer stem cells: Biomarker and therapeutic advances. *Neurochem. Int.* **2014**, *71*, 1–7. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
38. Singh, S.K.; Clarke, I.D.; Hide, T.; Dirks, P.B. Cancer stem cells in nervous system tumors. *Oncogene* **2004**, *23*, 7267–7273. [[CrossRef](#)] [[PubMed](#)]
39. Hambardzumyan, D.; Bergers, G. Glioblastoma: Defining Tumor Niches. *Trends Cancer* **2015**, *1*, 252–265. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
40. Chen, J.; Li, Y.; Yu, T.S.; McKay, R.M.; Burns, D.K.; Kernie, S.G.; Parada, L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* **2012**, *488*, 522–526. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
41. Dey, M.; Ulasov, I.V.; Lesniak, M.S. Virotherapy against malignant glioma stem cells. *Cancer Lett.* **2010**, *289*, 1–10. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
42. Hombach-Klonisch, S.; Mehrpour, M.; Shojaei, S.; Harlos, C.; Pitz, M.; Hamai, A.; Siemianowicz, K.; Likus, W.; Wiehac, E.; Toyota, B.D.; et al. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. *Pharmacol. Ther.* **2018**, *184*, 13–41. [[CrossRef](#)] [[PubMed](#)]
43. Farahani, E.; Patra, H.K.; Jangamreddy, J.R.; Rashedi, I.; Kawalec, M.; Rao Pariti, R.K.; Batakis, P.; Wiehac, E. Cell adhesion molecules and their relation to (cancer) cell stemness. *Carcinogenesis* **2014**, *35*, 747–759. [[CrossRef](#)] [[PubMed](#)]
44. Plaks, V.; Kong, N.; Werb, Z. The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? *Cell Stem Cell* **2015**, *16*, 225–238. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
45. Liang, J.; Piao, Y.; Holmes, L.; Fuller, G.N.; Henry, V.; Tiao, N.; de Groot, J.F. Neutrophils promote the malignant glioma phenotype through S100A4. *Clin. Cancer Res.* **2014**, *20*, 187–198. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
46. Badie, B.; Schartner, J. Role of microglia in glioma biology. *Microsc. Res. Tech.* **2001**, *54*, 106–113. [[CrossRef](#)] [[PubMed](#)]
47. Hambardzumyan, D.; Gutmann, D.H.; Kettenmann, H. The role of microglia and macrophages in glioma maintenance and progression. *Nat. Neurosci.* **2016**, *19*, 20–27. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
48. Becher, O.J.; Hambardzumyan, D.; Fomchenko, E.I.; Momota, H.; Mainwaring, L.; Bleau, A.M.; Katz, A.M.; Edgar, M.; Kenney, A.M.; Cordon-Cardo, C.; et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. *Cancer Res.* **2008**, *68*, 2241–2249. [[CrossRef](#)] [[PubMed](#)]
49. Edwards, L.A.; Woolard, K.; Son, M.J.; Li, A.; Lee, J.; Ene, C.; Mantey, S.A.; Maric, D.; Song, H.; Belova, G.; et al. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. *J. Natl. Cancer Inst.* **2011**, *103*, 1162–1178. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

50. Wang, Q.; Hu, B.; Hu, X.; Kim, H.; Squatrito, M.; Scarpaccia, L.; deCarvalho, A.C.; Lyu, S.; Li, P.; Li, Y.; et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. *Cancer Cell* **2017**, *32*, 42–56.e6. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
51. Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* **2010**, *17*, 98–110. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
52. Kolla, V.; Zhuang, T.; Higashi, M.; Naraparaju, K.; Brodeur, G.M. Role of CHD5 in human cancers: 10 years later. *Cancer Res.* **2014**, *74*, 652–658. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
53. Reifenger, G.; Liu, L.; Ichimura, K.; Schmidt, E.E.; Collins, V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. *Cancer Res.* **1993**, *53*, 2736–2739. [[PubMed](#)]
54. Toledo, F.; Wahl, G.M. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. *Nat. Rev. Cancer* **2006**, *6*, 909–923. [[CrossRef](#)] [[PubMed](#)]
55. Classon, M.; Harlow, E. The retinoblastoma tumour suppressor in development and cancer. *Nat. Rev. Cancer* **2002**, *2*, 910–917. [[CrossRef](#)] [[PubMed](#)]
56. Esteban-Villarrubia, J.; Soto-Castillo, J.J.; Pozas, J.; San Román-Gil, M.; Orejana-Martín, I.; Torres-Jiménez, J.; Carrato, A.; Alonso-Gordoa, T.; Molina-Cerrillo, J. Tyrosine Kinase Receptors in Oncology. *Int. J. Mol. Sci.* **2020**, *21*, 20201112. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
57. Li, E.; Hristova, K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. *Biochemistry* **2006**, *45*, 6241–6251. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
58. Frederick, L.; Wang, X.Y.; Eley, G.; James, C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. *Cancer Res.* **2000**, *60*, 1383–1387. [[PubMed](#)]
59. Lee, J.C.; Vivanco, I.; Beroukhi, R.; Huang, J.H.; Feng, W.L.; DeBiasi, R.M.; Yoshimoto, K.; King, J.C.; Nghiemphu, P.; Yuza, Y.; et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. *PLoS Med.* **2006**, *3*, e485. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
60. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* **2008**, *455*, 1061–1068. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
61. Ozawa, T.; Brennan, C.W.; Wang, L.; Squatrito, M.; Sasayama, T.; Nakada, M.; Huse, J.T.; Pedraza, A.; Utsuki, S.; Yasui, Y.; et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. *Genes Dev.* **2010**, *24*, 2205–2218. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
62. Zhang, Y.; Zhang, B.; Lv, C.; Zhang, N.; Xing, K.; Wang, Z.; Lv, R.; Yu, M.; Xu, C.; Wang, Y. Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma. *Theranostics* **2023**, *13*, 3744–3760. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
63. Alban, T.J.; Alvarado, A.G.; Sorensen, M.D.; Bayik, D.; Volovetz, J.; Serbinowski, E.; Mulkearns-Hubert, E.E.; Sinyuk, M.; Hale, J.S.; Onzi, G.R.; et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. *JCI Insight* **2018**, *3*, e122264. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
64. Miska, J.; Rashidi, A.; Lee-Chang, C.; Gao, P.; Lopez-Rosas, A.; Zhang, P.; Burga, R.; Castro, B.; Xiao, T.; Han, Y.; et al. Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. *Sci. Adv.* **2021**, *7*, eabc8929. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
65. Chanoch-Myers, R.; Wider, A.; Suva, M.L.; Tirosh, I. Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis. *Genome Med.* **2022**, *14*, 106. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
66. Wang, L.; Jung, J.; Babikir, H.; Shamardani, K.; Jain, S.; Feng, X.; Gupta, N.; Rosi, S.; Chang, S.; Raleigh, D.; et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. *Nat. Cancer* **2022**, *3*, 1534–1552. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
67. Perrault, E.N.; Shireman, J.M.; Ali, E.S.; Lin, P.; Preddy, I.; Park, C.; Budhiraja, S.; Baisiwala, S.; Dixit, K.; James, C.D.; et al. Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. *Sci. Adv.* **2023**, *9*, eade7236. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
68. Shireman, J.M.; Atashi, F.; Lee, G.; Ali, E.S.; Saathoff, M.R.; Park, C.H.; Savchuk, S.; Baisiwala, S.; Miska, J.; Lesniak, M.S.; et al. De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. *Brain* **2021**, *144*, 1230–1246. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
69. Ravi, V.M.; Neidert, N.; Will, P.; Joseph, K.; Maier, J.P.; Kückelhaus, J.; Vollmer, L.; Goeldner, J.M.; Behringer, S.P.; Scherer, F.; et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. *Nat. Commun.* **2022**, *13*, 925. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
70. Ravi, V.M.; Will, P.; Kueckelhaus, J.; Sun, N.; Joseph, K.; Salié, H.; Vollmer, L.; Kuliesiute, U.; von Ehr, J.; Benotmane, J.K.; et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. *Cancer Cell* **2022**, *40*, 639–655.e13. [[CrossRef](#)] [[PubMed](#)]
71. Ren, Y.; Huang, Z.; Zhou, L.; Xiao, P.; Song, J.; He, P.; Xie, C.; Zhou, R.; Li, M.; Dong, X.; et al. Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas. *Nat. Commun.* **2023**, *14*, 1028. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

72. Greenwald, A.C.; Darnell, N.G.; Hoefflin, R.; Simkin, D.; Mount, C.W.; Gonzalez Castro, L.N.; Harnik, Y.; Dumont, S.; Hirsch, D.; Nomura, M.; et al. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. *Cell* **2024**, *187*, 2485–2501.e26. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
73. De Silva, M.I.; Stringer, B.W.; Bardy, C. Neuronal and tumorigenic boundaries of glioblastoma plasticity. *Trends Cancer* **2023**, *9*, 223–236. [[CrossRef](#)] [[PubMed](#)]
74. Neftel, C.; Laffy, J.; Filbin, M.G.; Hara, T.; Shore, M.E.; Rahme, G.J.; Richman, A.R.; Silverbush, D.; Shaw, M.L.; Hebert, C.M.; et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. *Cell* **2019**, *178*, 835–849.e21. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
75. Suvà, M.L.; Tirosh, I. The Glioma Stem Cell Model in the Era of Single-Cell Genomics. *Cancer Cell* **2020**, *37*, 630–636. [[CrossRef](#)] [[PubMed](#)]
76. Couturier, C.P.; Ayyadury, S.; Le, P.U.; Nadaf, J.; Monlong, J.; Riva, G.; Allache, R.; Baig, S.; Yan, X.; Bourgey, M.; et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. *Nat. Commun.* **2020**, *11*, 3406. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
77. Phillips, H.S.; Kharbanda, S.; Chen, R.; Forrest, W.F.; Soriano, R.H.; Wu, T.D.; Misra, A.; Nigro, J.M.; Colman, H.; Soroceanu, L.; et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* **2006**, *9*, 157–173. [[CrossRef](#)] [[PubMed](#)]
78. Sottoriva, A.; Spiteri, I.; Piccirillo, S.G.; Touloumis, A.; Collins, V.P.; Marioni, J.C.; Curtis, C.; Watts, C.; Tavaré, S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 4009–4014. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
79. Behnan, J.; Finocchiaro, G.; Hanna, G. The landscape of the mesenchymal signature in brain tumours. *Brain* **2019**, *142*, 847–866. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
80. Bhat, K.P.L.; Balasubramaniyan, V.; Vaillant, B.; Ezhilarasan, R.; Hummelink, K.; Hollingsworth, F.; Wani, K.; Heathcock, L.; James, J.D.; Goodman, L.D.; et al. Mesenchymal differentiation mediated by NF- κ B promotes radiation resistance in glioblastoma. *Cancer Cell* **2013**, *24*, 331–346. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
81. Singh, S.K.; Fiorelli, R.; Kupp, R.; Rajan, S.; Szeto, E.; Lo Cascio, C.; Maire, C.L.; Sun, Y.; Alberta, J.A.; Eschbacher, J.M.; et al. Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF- β Pathway. *Cell Rep.* **2016**, *16*, 950–966. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
82. Sciacovelli, M.; Frezza, C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. *FEBS J.* **2017**, *284*, 3132–3144. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
83. Liu, T.; Ma, W.; Xu, H.; Huang, M.; Zhang, D.; He, Z.; Zhang, L.; Brem, S.; O'Rourke, D.M.; Gong, Y.; et al. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. *Nat. Commun.* **2018**, *9*, 3439. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
84. Piao, Y.; Liang, J.; Holmes, L.; Henry, V.; Sulman, E.; de Groot, J.F. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. *Clin. Cancer Res.* **2013**, *19*, 4392–4403. [[CrossRef](#)] [[PubMed](#)]
85. Segerman, A.; Niklasson, M.; Haglund, C.; Bergström, T.; Jarvius, M.; Xie, Y.; Westermarck, A.; Sönmez, D.; Hermansson, A.; Kastemar, M.; et al. Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition. *Cell Rep.* **2016**, *17*, 2994–3009. [[CrossRef](#)] [[PubMed](#)]
86. Halliday, J.; Helmy, K.; Pattwell, S.S.; Pitter, K.L.; LaPlant, Q.; Ozawa, T.; Holland, E.C. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 5248–5253. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
87. Martinez, R.; Rohde, V.; Schackert, G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. *J. Neuro-Oncol.* **2010**, *96*, 321–329. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
88. Takashima, Y.; Kawaguchi, A.; Yamanaka, R. Promising Prognosis Marker Candidates on the Status of Epithelial-Mesenchymal Transition and Glioma Stem Cells in Glioblastoma. *Cells* **2019**, *8*, 1312. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
89. Fedele, M.; Cerchia, L.; Pegoraro, S.; Sgarra, R.; Manfioletti, G. Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma. *Int. J. Mol. Sci.* **2019**, *20*, 2746. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
90. Kim, J.; Lee, I.H.; Cho, H.J.; Park, C.K.; Jung, Y.S.; Kim, Y.; Nam, S.H.; Kim, B.S.; Johnson, M.D.; Kong, D.S.; et al. Spatiotemporal Evolution of the Primary Glioblastoma Genome. *Cancer Cell* **2015**, *28*, 318–328. [[CrossRef](#)] [[PubMed](#)]
91. Lai, Y.; Lu, X.; Liao, Y.; Ouyang, P.; Wang, H.; Zhang, X.; Huang, G.; Qi, S.; Li, Y. Crosstalk between glioblastoma and tumor microenvironment drives proneural-mesenchymal transition through ligand-receptor interactions. *Genes Dis.* **2024**, *11*, 874–889. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
92. Herting, C.J.; Chen, Z.; Pitter, K.L.; Szulzewsky, F.; Kaffes, I.; Kaluzova, M.; Park, J.C.; Cimino, P.J.; Brennan, C.; Wang, B.; et al. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas. *Glia* **2017**, *65*, 1914–1926. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
93. Su, X.; Yang, Y.; Guo, C.; Zhang, R.; Sun, S.; Wang, Y.; Qiao, Q.; Fu, Y.; Pang, Q. NOX4-Derived ROS Mediates TGF- β 1-Induced Metabolic Reprogramming during Epithelial-Mesenchymal Transition through the PI3K/AKT/HIF-1 α Pathway in Glioblastoma. *Oxid. Med. Cell. Longev.* **2021**, *2021*, 5549047. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

94. Talasila, K.M.; Røslund, G.V.; Hagland, H.R.; Eskilsson, E.; Flønes, I.H.; Fritah, S.; Azuaje, F.; Atai, N.; Harter, P.N.; Mittelbronn, M.; et al. The angiogenic switch leads to a metabolic shift in human glioblastoma. *Neuro-Oncology* **2017**, *19*, 383–393. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
95. Yang, M.; Chen, X.; Zhang, J.; Xiong, E.; Wang, Q.; Fang, W.; Li, L.; Fei, F.; Gong, A. ME2 Promotes Proneural-Mesenchymal Transition and Lipogenesis in Glioblastoma. *Front. Oncol.* **2021**, *11*, 715593. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
96. Lau, J.; Ilkhanizadeh, S.; Wang, S.; Miroshnikova, Y.A.; Salvatierra, N.A.; Wong, R.A.; Schmidt, C.; Weaver, V.M.; Weiss, W.A.; Persson, A.I. STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma. *Cancer Res.* **2015**, *75*, 4302–4311. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
97. Minata, M.; Audia, A.; Shi, J.; Lu, S.; Bernstock, J.; Pavlyukov, M.S.; Das, A.; Kim, S.H.; Shin, Y.J.; Lee, Y.; et al. Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. *Cell Rep.* **2019**, *26*, 1893–1905.e7. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
98. Wood, M.D.; Reis, G.F.; Reuss, D.E.; Phillips, J.J. Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence. *J. Neuropathol. Exp. Neurol.* **2016**, *75*, 925–935. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
99. Timke, C.; Zieher, H.; Roth, A.; Hauser, K.; Lipson, K.E.; Weber, K.J.; Debus, J.; Abdollahi, A.; Huber, P.E. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. *Clin. Cancer Res.* **2008**, *14*, 2210–2219. [[CrossRef](#)] [[PubMed](#)]
100. Zhou, Y.C.; Liu, J.Y.; Li, J.; Zhang, J.; Xu, Y.Q.; Zhang, H.W.; Qiu, L.B.; Ding, G.R.; Su, X.M.; Mei, S.; et al. Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition. *Int. J. Radiat. Oncol. Biol. Phys.* **2011**, *81*, 1530–1537. [[CrossRef](#)] [[PubMed](#)]
101. Zhang, X.; Wang, X.; Xu, R.; Ji, J.; Xu, Y.; Han, M.; Wei, Y.; Huang, B.; Chen, A.; Zhang, Q.; et al. YM155 decreases radiation-induced invasion and reverses epithelial-mesenchymal transition by targeting STAT3 in glioblastoma. *J. Transl. Med.* **2018**, *16*, 79. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
102. Moreno, M.; Pedrosa, L.; Paré, L.; Pineda, E.; Bejarano, L.; Martínez, J.; Balasubramaniyan, V.; Ezhilarasan, R.; Kallarackal, N.; Kim, S.H.; et al. GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. *Cell Rep.* **2017**, *21*, 2183–2197. [[CrossRef](#)] [[PubMed](#)]
103. Chen, C.; Han, G.; Li, Y.; Yue, Z.; Wang, L.; Liu, J. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma. *J. Cell. Biochem.* **2019**, *120*, 882–893. [[CrossRef](#)] [[PubMed](#)]
104. Johnson, B.E.; Mazar, T.; Hong, C.; Barnes, M.; Aihara, K.; McLean, C.Y.; Fouse, S.D.; Yamamoto, S.; Ueda, H.; Tatsuno, K.; et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science* **2014**, *343*, 189–193. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
105. Prins, R.M.; Soto, H.; Konkankit, V.; Odesa, S.K.; Eskin, A.; Yong, W.H.; Nelson, S.F.; Liau, L.M. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. *Clin. Cancer Res.* **2011**, *17*, 1603–1615. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
106. Tejero, R.; Huang, Y.; Katsyv, I.; Kluge, M.; Lin, J.Y.; Tome-Garcia, J.; Daviaud, N.; Wang, Y.; Zhang, B.; Tsankova, N.M.; et al. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. *eBioMedicine* **2019**, *42*, 252–269. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
107. Wang, J.; Zhou, F.; Li, Y.; Li, Q.; Wu, Z.; Yu, L.; Yuan, F.; Liu, J.; Tian, Y.; Cao, Y.; et al. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition. *Cell Cycle (Georget. Tex.)* **2017**, *16*, 2355–2365. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
108. Dumas, A.A.; Pomella, N.; Rosser, G.; Guglielmi, L.; Vinel, C.; Millner, T.O.; Rees, J.; Aley, N.; Sheer, D.; Wei, J.; et al. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. *EMBO J.* **2020**, *39*, e103790. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
109. Chinot, O.L.; Wick, W.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R.; Carpentier, A.F.; Hoang-Xuan, K.; Kavan, P.; Cernea, D.; et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N. Engl. J. Med.* **2014**, *370*, 709–722. [[CrossRef](#)] [[PubMed](#)]
110. Gilbert, M.R.; Dignam, J.J.; Armstrong, T.S.; Wefel, J.S.; Blumenthal, D.T.; Vogelbaum, M.A.; Colman, H.; Chakravarti, A.; Pugh, S.; Won, M.; et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N. Engl. J. Med.* **2014**, *370*, 699–708. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
111. Wick, W.; Platten, M.; Wick, A.; Hertenstein, A.; Radbruch, A.; Bendszus, M.; Winkler, F. Current status and future directions of anti-angiogenic therapy for gliomas. *Neuro-Oncology* **2016**, *18*, 315–328. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
112. Piao, Y.; Liang, J.; Holmes, L.; Zurita, A.J.; Henry, V.; Heymach, J.V.; de Groot, J.F. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. *Neuro-Oncology* **2012**, *14*, 1379–1392. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
113. Puchalski, R.B.; Shah, N.; Miller, J.; Dalley, R.; Nomura, S.R.; Yoon, J.G.; Smith, K.A.; Lankovitch, M.; Bertagnoli, D.; Bickley, K.; et al. An anatomic transcriptional atlas of human glioblastoma. *Science* **2018**, *360*, 660–663. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
114. Fink, J.R.; Muzi, M.; Peck, M.; Krohn, K.A. Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. *J. Nucl. Med.* **2015**, *56*, 1554–1561. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

115. Horská, A.; Barker, P.B. Imaging of brain tumors: MR spectroscopy and metabolic imaging. *Neuroimaging Clin. N. Am.* **2010**, *20*, 293–310. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
116. Jensen, T.R.; Schmainda, K.M. Computer-aided detection of brain tumor invasion using multiparametric MRI. *J. Magn. Reson. Imaging* **2009**, *30*, 481–489. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
117. Civita, P.; Franceschi, S.; Aretini, P.; Ortenzi, V.; Menicagli, M.; Lessi, F.; Pasqualetti, F.; Naccarato, A.G.; Mazzanti, C.M. Laser Capture Microdissection and RNA-Seq Analysis: High Sensitivity Approaches to Explain Histopathological Heterogeneity in Human Glioblastoma FFPE Archived Tissues. *Front. Oncol.* **2019**, *9*, 482. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
118. De Palma, M.; Biziato, D.; Petrova, T.V. Microenvironmental regulation of tumour angiogenesis. *Nat. Rev. Cancer* **2017**, *17*, 457–474. [[CrossRef](#)] [[PubMed](#)]
119. Harris, A.L. Hypoxia—a key regulatory factor in tumour growth. *Nat. Rev. Cancer* **2002**, *2*, 38–47. [[CrossRef](#)] [[PubMed](#)]
120. Monteiro, A.R.; Hill, R.; Pilkington, G.J.; Madureira, P.A. The Role of Hypoxia in Glioblastoma Invasion. *Cells* **2017**, *6*, 45. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
121. Joseph, J.V.; Conroy, S.; Pavlov, K.; Sontakke, P.; Tomar, T.; Eggens-Meijer, E.; Balasubramanian, V.; Wagemakers, M.; den Dunnen, W.F.; Kruij, F.A. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1 α -ZEB1 axis. *Cancer Lett.* **2015**, *359*, 107–116. [[CrossRef](#)] [[PubMed](#)]
122. Qiu, W.; Song, S.; Chen, W.; Zhang, J.; Yang, H.; Chen, Y. Hypoxia-induced EPHB2 promotes invasive potential of glioblastoma. *Int. J. Clin. Exp. Pathol.* **2019**, *12*, 539–548. [[PubMed](#)] [[PubMed Central](#)]
123. Jin, P.; Shin, S.H.; Chun, Y.S.; Shin, H.W.; Shin, Y.J.; Lee, Y.; Kim, D.; Nam, D.H.; Park, J.W. Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF- κ B signaling pathway. *Oncogene* **2018**, *37*, 3070–3087. [[CrossRef](#)] [[PubMed](#)]
124. Niklasson, M.; Bergström, T.; Jarvius, M.; Sundström, A.; Nyberg, F.; Haglund, C.; Larsson, R.; Westermark, B.; Segerman, B.; Segerman, A. Mesenchymal transition and increased therapy resistance of glioblastoma cells is related to astrocyte reactivity. *J. Pathol.* **2019**, *249*, 295–307. [[CrossRef](#)] [[PubMed](#)]
125. Doucette, T.; Rao, G.; Rao, A.; Shen, L.; Aldape, K.; Wei, J.; Dziurzynski, K.; Gilbert, M.; Heimberger, A.B. Immune heterogeneity of glioblastoma subtypes: Extrapolation from the cancer genome atlas. *Cancer Immunol. Res.* **2013**, *1*, 112–122. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
126. Rutledge, W.C.; Kong, J.; Gao, J.; Gutman, D.A.; Cooper, L.A.; Appin, C.; Park, Y.; Scarpace, L.; Mikkelsen, T.; Cohen, M.L.; et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. *Clin. Cancer Res.* **2013**, *19*, 4951–4960. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
127. Beier, C.P.; Kumar, P.; Meyer, K.; Leukel, P.; Bruttel, V.; Aschenbrenner, I.; Riemenschneider, M.J.; Fragoulis, A.; Rümmele, P.; Lamszus, K.; et al. The cancer stem cell subtype determines immune infiltration of glioblastoma. *Stem Cells Dev.* **2012**, *21*, 2753–2761. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
128. Engler, J.R.; Robinson, A.E.; Smirnov, I.; Hodgson, J.G.; Berger, M.S.; Gupta, N.; James, C.D.; Molinaro, A.; Phillips, J.J. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. *PLoS ONE* **2012**, *7*, e43339. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
129. Sørensen, M.D.; Dahlrot, R.H.; Boldt, H.B.; Hansen, S.; Kristensen, B.W. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. *Neuropathol. Appl. Neurobiol.* **2018**, *44*, 185–206. [[CrossRef](#)] [[PubMed](#)]
130. Kaffes, I.; Szulzewsky, F.; Chen, Z.; Herting, C.J.; Gabanic, B.; Velázquez Vega, J.E.; Shelton, J.; Switchenko, J.M.; Ross, J.L.; McSwain, L.F.; et al. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. *Oncoimmunology* **2019**, *8*, e1655360. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
131. Zanutto-Filho, A.; Gonçalves, R.M.; Klafke, K.; de Souza, P.O.; Dillenburg, F.C.; Carro, L.; Gelain, D.P.; Moreira, J.C. Inflammatory landscape of human brain tumors reveals an NF κ B dependent cytokine pathway associated with mesenchymal glioblastoma. *Cancer Lett.* **2017**, *390*, 176–187. [[CrossRef](#)] [[PubMed](#)]
132. Hara, T.; Chanoch-Myers, R.; Mathewson, N.D.; Myskiw, C.; Atta, L.; Bussema, L.; Eichhorn, S.W.; Greenwald, A.C.; Kinker, G.S.; Rodman, C.; et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. *Cancer Cell* **2021**, *39*, 779–792.e11. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
133. Arbab, A.S.; Rashid, M.H.; Angara, K.; Borin, T.F.; Lin, P.C.; Jain, M.; Achyut, B.R. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. *Int. J. Mol. Sci.* **2017**, *18*, 2732. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
134. Ye, Z.; Ai, X.; Zhao, L.; Fei, F.; Wang, P.; Zhou, S. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. *Oncogene* **2021**, *40*, 6059–6070. [[CrossRef](#)] [[PubMed](#)]
135. Broekman, M.L.; Maas, S.L.N.; Abels, E.R.; Mempel, T.R.; Krichevsky, A.M.; Breakefield, X.O. Multidimensional communication in the microenvirons of glioblastoma. *Nat. Rev. Neurol.* **2018**, *14*, 482–495. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
136. Brandenburg, S.; Müller, A.; Turkowski, K.; Radev, Y.T.; Rot, S.; Schmidt, C.; Bungert, A.D.; Acker, G.; Schorr, A.; Hippe, A.; et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. *Acta Neuropathol.* **2016**, *131*, 365–378. [[CrossRef](#)] [[PubMed](#)]
137. Poon, C.C.; Sarkar, S.; Yong, V.W.; Kelly, J.J.P. Glioblastoma-associated microglia and macrophages: Targets for therapies to improve prognosis. *Brain* **2017**, *140*, 1548–1560. [[CrossRef](#)] [[PubMed](#)]

138. Cooper, L.A.; Gutman, D.A.; Chisolm, C.; Appin, C.; Kong, J.; Rong, Y.; Kurc, T.; Van Meir, E.G.; Saltz, J.H.; Moreno, C.S.; et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. *Am. J. Pathol.* **2012**, *180*, 2108–2119. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
139. Caverzán, M.D.; Beaugé, L.; Oliveda, P.M.; Cesca González, B.; Bühler, E.M.; Ibarra, L.E. Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies. *Brain Sci.* **2023**, *13*, 542. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
140. Pombo Antunes, A.R.; Scheyltjens, I.; Duerinck, J.; Neyns, B.; Movahedi, K.; Van Ginderachter, J.A. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. *eLife* **2020**, *9*, e52176. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
141. Li, C.W.; Xia, W.; Huo, L.; Lim, S.O.; Wu, Y.; Hsu, J.L.; Chao, C.H.; Yamaguchi, H.; Yang, N.K.; Ding, Q.; et al. Epithelial-mesenchymal transition induced by TNF- α requires NF- κ B-mediated transcriptional upregulation of Twist1. *Cancer Res.* **2012**, *72*, 1290–1300. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
142. Taniguchi, K.; Karin, M. NF- κ B, inflammation, immunity and cancer: Coming of age. *Nat. Rev. Immunol.* **2018**, *18*, 309–324. [[CrossRef](#)] [[PubMed](#)]
143. De Craene, B.; Berx, G. Regulatory networks defining EMT during cancer initiation and progression. *Nat. Rev. Cancer* **2013**, *13*, 97–110. [[CrossRef](#)] [[PubMed](#)]
144. Min, C.; Eddy, S.F.; Sherr, D.H.; Sonenshein, G.E. NF-kappaB and epithelial to mesenchymal transition of cancer. *J. Cell. Biochem.* **2008**, *104*, 733–744. [[CrossRef](#)] [[PubMed](#)]
145. Fan, Y.; Mao, R.; Yang, J. NF- κ B and STAT3 signaling pathways collaboratively link inflammation to cancer. *Protein Cell* **2013**, *4*, 176–185. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
146. Carro, M.S.; Lim, W.K.; Alvarez, M.J.; Bollo, R.J.; Zhao, X.; Snyder, E.Y.; Sulman, E.P.; Anne, S.L.; Doetsch, F.; Colman, H.; et al. The transcriptional network for mesenchymal transformation of brain tumours. *Nature* **2010**, *463*, 318–325. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
147. Bhat, K.P.; Salazar, K.L.; Balasubramanian, V.; Wani, K.; Heathcock, L.; Hollingsworth, F.; James, J.D.; Gumin, J.; Diefes, K.L.; Kim, S.H.; et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. *Genes Dev.* **2011**, *25*, 2594–2609. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
148. Yee, P.P.; Wei, Y.; Kim, S.Y.; Lu, T.; Chih, S.Y.; Lawson, C.; Tang, M.; Liu, Z.; Anderson, B.; Thamburaj, K.; et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. *Nat. Commun.* **2020**, *11*, 5424. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
149. Vigneswaran, K.; Boyd, N.H.; Oh, S.Y.; Lallani, S.; Boucher, A.; Neill, S.G.; Olson, J.J.; Read, R.D. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. *Clin. Cancer Res.* **2021**, *27*, 1553–1569. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
150. Yamini, B. NF- κ B, Mesenchymal Differentiation and Glioblastoma. *Cells* **2018**, *7*, 125. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
151. Wang, D.; Berglund, A.E.; Kenchappa, R.S.; MacAulay, R.J.; Mule, J.J.; Etame, A.B. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats. *Sci. Rep.* **2017**, *7*, 9350. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
152. Wang, D.; Berglund, A.; Kenchappa, R.S.; Forsyth, P.A.; Mule, J.J.; Etame, A.B. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma. *Sci. Rep.* **2016**, *6*, 21710. [[CrossRef](#)] [[PubMed](#)]
153. Yin, J.; Oh, Y.T.; Kim, J.Y.; Kim, S.S.; Choi, E.; Kim, T.H.; Hong, J.H.; Chang, N.; Cho, H.J.; Sa, J.K.; et al. Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBP β Signaling. *Cancer Res.* **2017**, *77*, 4973–4984. [[CrossRef](#)] [[PubMed](#)]
154. Chow, K.H.; Park, H.J.; George, J.; Yamamoto, K.; Gallup, A.D.; Graber, J.H.; Chen, Y.; Jiang, W.; Steindler, D.A.; Neilson, E.G.; et al. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. *Cancer Res.* **2017**, *77*, 5360–5373. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
155. Jiang, Y.; Zhou, J.; Hou, D.; Luo, P.; Gao, H.; Ma, Y.; Chen, Y.S.; Li, L.; Zou, D.; Zhang, H.; et al. Prosaposin is a biomarker of mesenchymal glioblastoma and regulates mesenchymal transition through the TGF- β 1/Smad signaling pathway. *J. Pathol.* **2019**, *249*, 26–38. [[CrossRef](#)] [[PubMed](#)]
156. Brodie, S.; Lee, H.K.; Jiang, W.; Cazacu, S.; Xiang, C.; Poisson, L.M.; Datta, I.; Kalkanis, S.; Ginsberg, D.; Brodie, C. The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells. *Oncotarget* **2017**, *8*, 31785–31801. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
157. Du, X.; Tu, Y.; Liu, S.; Zhao, P.; Bao, Z.; Li, C.; Li, J.; Pan, M.; Ji, J. LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop. *J. Cell. Mol. Med.* **2020**, *24*, 1474–1487. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
158. Li, C.; Zheng, H.; Hou, W.; Bao, H.; Xiong, J.; Che, W.; Gu, Y.; Sun, H.; Liang, P. Long non-coding RNA linc00645 promotes TGF- β -induced epithelial-mesenchymal transition by regulating miR-205-3p-ZEB1 axis in glioma. *Cell Death Dis.* **2019**, *10*, 717. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
159. Fu, Q.; Li, S.; Zhou, Q.; Yalikun, K.; Yisireyili, D.; Xia, M. Low LINC00599 expression is a poor prognostic factor in glioma. *Biosci. Rep.* **2019**, *39*, BSR20190232. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

160. He, X.; Liu, Z.; Peng, Y.; Yu, C. MicroRNA-181c inhibits glioblastoma cell invasion, migration and mesenchymal transition by targeting TGF- β pathway. *Biochem. Biophys. Res. Commun.* **2016**, *469*, 1041–1048. [[CrossRef](#)] [[PubMed](#)]
161. Zhang, Y.; Zeng, A.; Liu, S.; Li, R.; Wang, X.; Yan, W.; Li, H.; You, Y. Genome-wide identification of epithelial-mesenchymal transition-associated microRNAs reveals novel targets for glioblastoma therapy. *Oncol. Lett.* **2018**, *15*, 7625–7630. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
162. Huang, B.S.; Luo, Q.Z.; Han, Y.; Huang, D.; Tang, Q.P.; Wu, L.X. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway. *J. Cell. Biochem.* **2017**, *118*, 3452–3461. [[CrossRef](#)] [[PubMed](#)]
163. Feng, S.; Yao, J.; Zhang, Z.; Zhang, Y.; Zhang, Z.; Liu, J.; Tan, W.; Sun, C.; Chen, L.; Yu, X. miR-96 inhibits EMT by targeting AEG-1 in glioblastoma cancer cells. *Mol. Med. Rep.* **2018**, *17*, 2964–2972. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
164. Li, L.; Shao, M.Y.; Zou, S.C.; Xiao, Z.F.; Chen, Z.C. MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44. *J. Neurooncol* **2019**, *141*, 19–30. [[CrossRef](#)] [[PubMed](#)]
165. Urdiciain, A.; Erausquin, E.; Meléndez, B.; Rey, J.A.; Idoate, M.A.; Castresana, J.S. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells. *Int. J. Oncol.* **2019**, *54*, 1797–1808. [[CrossRef](#)] [[PubMed](#)]
166. Vincure, O.S.; Sharma, V.; Tabasum, S.; Ghosh, S.; Singh, R.P.; Sarkar, C.; Kulshreshtha, R. Polycomb complex mediated epigenetic reprogramming alters TGF- β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas. *Int. J. Cancer* **2019**, *145*, 1254–1269. [[CrossRef](#)] [[PubMed](#)]
167. Wu, Q.; Berglund, A.E.; Etame, A.B. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. *Int. J. Mol. Sci.* **2021**, *22*, 8324. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
168. Yu, T.; Wang, Y.; Hu, Q.; Wu, W.; Wu, Y.; Wei, W.; Han, D.; You, Y.; Lin, N.; Liu, N. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. *Oncotarget* **2017**, *8*, 98348–98359. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
169. Liu, Z.; Wang, Z.; Chen, D.; Liu, X.; Yu, G.; Zhang, Y.; Chen, C.; Xu, R.; Wang, Y.; Liu, R.E. Paeoniflorin Inhibits EMT and Angiogenesis in Human Glioblastoma via K63-Linked C-Met Polyubiquitination-Dependent Autophagic Degradation. *Front. Oncol.* **2022**, *12*, 785345. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
170. Burghardt, I.; Tritschler, F.; Opitz, C.A.; Frank, B.; Weller, M.; Wick, W. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. *Biochem. Biophys. Res. Commun.* **2007**, *354*, 542–547. [[CrossRef](#)] [[PubMed](#)]
171. Kim, J.K.; Jin, X.; Sohn, Y.W.; Jin, X.; Jeon, H.Y.; Kim, E.J.; Ham, S.W.; Jeon, H.M.; Chang, S.Y.; Oh, S.Y.; et al. Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling. *Cancer Lett.* **2014**, *353*, 194–200. [[CrossRef](#)] [[PubMed](#)]
172. Dong, Z.; Zhou, L.; Han, N.; Zhang, M.; Lyu, X. Wnt/ β -catenin pathway involvement in ionizing radiation-induced invasion of U87 glioblastoma cells. *Strahlenther. Onkol.* **2015**, *191*, 672–680. [[CrossRef](#)] [[PubMed](#)]
173. Yi, G.Z.; Liu, Y.W.; Xiang, W.; Wang, H.; Chen, Z.Y.; Xie, S.D.; Qi, S.T. Akt and β -catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. *J. Neurol. Sci.* **2016**, *367*, 101–106. [[CrossRef](#)] [[PubMed](#)]
174. Song, Y.; Chen, Y.; Li, Y.; Lyu, X.; Cui, J.; Cheng, Y.; Zhao, L.; Zhao, G. Metformin inhibits TGF- β 1-induced epithelial-to-mesenchymal transition-like process and stem-like properties in GBM via AKT/mTOR/ZEB1 pathway. *Oncotarget* **2018**, *9*, 7023–7035. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
175. Yuan, X.; Wei, W.; Bao, Q.; Chen, H.; Jin, P.; Jiang, W. Metformin inhibits glioma cells stemness and epithelial-mesenchymal transition via regulating YAP activity. *Biomed. Pharmacother.* **2018**, *102*, 263–270. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.